ZYDUS LIFESCIENCES
|
|
| BOM : 532321 NSE : ZYDUSLIFE | |
| LT :
Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued] Debt : High |
Updated: |
| ST :
Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : NA |
Mar 28,2023 |
|
Price(EOD): ₹ 484.40
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 49,030.97 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ZYDUS LIFESCIENCES | 1.2% | 3.8% | 34.4% |
| SUN PHARMACEUTICAL INDUSTRIES | 1.3% | 1.4% | 9.1% |
| DIVIS LABORATORIES | 0.6% | -3.8% | -36.5% |
| CIPLA | 3% | -7.7% | -12.2% |
| DR REDDYS LABORATORIES | 1.2% | 0.6% | 2.9% |
| TORRENT PHARMACEUTICALS | 1.6% | 4% | 11.9% |
| ABBOTT INDIA | 0.6% | 6.9% | 33.6% |
| ALKEM LABORATORIES | 0.9% | -1.5% | -10.7% |
| LUPIN | -2.3% | -2.3% | -12.9% |
FUNDAMENTAL ANALYSIS OF ZYDUS LIFESCIENCES
[ Q(TTM): Dec2022, Y: Mar2022
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF ZYDUS LIFESCIENCES
[As on : Mar 28,2023
]
| Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
23.16
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 2,117.00 Cr
[Latest Qtr - Dec2022 - Consolidated Results ] 2.88
P/B Calculated based on Book Value of Rs 16,999.60 Cr
[Latest Year - Mar2022 - Consolidated Results ] 2.98
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 16,433.50 Cr
[Latest Qtr - Dec2022 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
8% -6% 6% |
SHARE PRICE MOMENTUM OF ZYDUS LIFESCIENCES
ZYDUS LIFESCIENCES vs SENSEX
DEBT OF ZYDUS LIFESCIENCES
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2022 2021 2020 Avg_3yrs |
0.2 0.31 0.33 0.28 |
0.25 0.35 0.77 0.46 |
|
[Last Annual Data : Mar2022]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF ZYDUS LIFESCIENCES
| Pledged Promoter Shares |
NA | |
|---|---|---|
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF ZYDUS LIFESCIENCES
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
5.5% 17.26% 21.36% 15.64% |
19.85% 27.2% 29.11% 18.21% |
| QtrlyTrend |
8 | |
| Latest Qtr: Dec2022 | ||
| Quarterly Result Analysis → | ||
ZYDUS LIFESCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE HEALTHCARE | 1% | -1.3% | -11.5% |
| S&P BSE LARGECAP | -1% | -2.8% | -3.1% |
| S&P BSE 200 | -1.2% | -2.9% | -2.9% |
| S&P BSE LARGE MIDCAP | -1.2% | -2.9% | -3% |
| S&P BSE 250 LARGEMIDCAP | -1.2% | -2.9% | -3.1% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY HEALTHCARE | 2.1% | -1.1% | -11.9% |
| NIFTY PHARMA | 2.1% | -0.8% | -13.5% |
| NIFTY 200 | -1.2% | -2.8% | -3.1% |
| NIFTY 500 | -1.4% | -3.1% | -3.3% |
| NIFTY LARGE MIDCAP 250 | -1.6% | -3% | -1.4% |
You may also like the below Video Courses
FAQ about ZYDUS LIFESCIENCES
Is ZYDUS LIFESCIENCES good for long term investment?
As on Mar 28,2023, the Fundamentals of ZYDUS LIFESCIENCES look Strong and hence it may be good for long term investment! See Financial Performance of ZYDUS LIFESCIENCES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is ZYDUS LIFESCIENCES UnderValued or OverValued?
As on Mar 28,2023, ZYDUS LIFESCIENCES is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of ZYDUS LIFESCIENCES ?
As on Mar 28,2023, the Intrinsic Value of ZYDUS LIFESCIENCES is Rs. 457.39 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 448.78
Fair Value [Median EV / Sales Model] : Rs. 517.29
Fair Value [Median Price / Sales Model] : Rs. 457.39
Estimated Median Fair Value of ZYDUS LIFESCIENCES : Rs. 457.39
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is ZYDUS LIFESCIENCES trading at a Premium or Discount?
As on Mar 28,2023, ZYDUS LIFESCIENCES is trading at a Premium of 6% based on the estimates of Median Intrinsic Value!
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].
